Summary Medical Devices sector report, “COVID 19 Nucleic Acid Amplification Tests (NAATs) - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the COVID 19 Nucleic Acid Amplification Tests (NAATs) pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.
COVID 19 NAAT tests are highly sensitive tests and can easily detect the low density infections. The types of NAAT tests are Polymerase chain reaction (PCR) – including nested (n), quantitative (q) or real-time reverse transcription (RT) PCR), quantitative nucleic acid sequence-based amplification (QT-NASBA) and loop mediated isothermal amplification (LAMP).
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.
Scope - Extensive coverage of the COVID 19 Nucleic Acid Amplification Tests (NAATs) under development
- The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
- The report reviews the major players involved in the development of COVID 19 Nucleic Acid Amplification Tests (NAATs) and list all their pipeline projects
- The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
- The report provides key clinical trial data of ongoing trials specific to pipeline products
- Recent developments in the segment / industry
Reasons to Buy The report enables you to -
- Formulate significant competitor information, analysis, and insights to improve R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of COVID 19 Nucleic Acid Amplification Tests (NAATs) under development
- Develop market-entry and market expansion strategies
- Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
- In-depth analysis of the product’s current stage of development, territory and estimated launch date
Our reports have been used by over 10K customers, including:
Certain factors that are driving the market growth include the increased incidence of cancer, globally, and higher acceptance of treatments for cancer in the developing regions, the paradigm shift in healthcare, from disease diagnosis to risk assessment or early diagnosis, and increasing usage of biomarkers in drug development. - Globally,...
Increasing emphasis on early disease detection and prevention is expected to drive the growth of the global carrier screening market. The global carrier screening market size is expected to grow from USD 1.8 billion in 2019 to USD 4.0 billion by 2024, at a CAGR of 17.5% during the forecast period. Growth in the carrier...
Anatomic pathology track and trace solutions market projected to grow at a CAGR of 10.4% The anatomic pathology track and trace solutions market is projected to reach USD 695.7 million by 2023 from USD 424.2 million in 2018, at a CAGR of 10.4% from 2018 to 2023. The increasing volume of diagnostic tests performed in anatomic...
The global thermal interface materials market is expected to reach USD 3.59 billion by 2025, according to a new report by Grand View Research, Inc. Thermal interface materials are expected to witness substantial gains over the forecast period on account of their increasing usage in automotive, medical and consumer goods applications. Growing...
95 pages •
By Infiniti Research Limited
• Feb 2017
About Anatomic Pathology Testing
The anatomic pathology testing helps in identifying abnormalities in tissue or cell lines and develops personalized care treatment. It helps to evaluate different types of cancers such as lung cancer, breast cancer, colorectal cancer, and chronic conditions such as kidney or liver disease, infectious...
Pathology
Cancer
Healthcare IT
Clinical Diagnostic
United States
Europe
APAC
Drug Approval
Cancer Incidence
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.